

Dr. Jennifer Taylor-Cousar is a fellowshiptrained pulmonologist and researcher who specializes in cystic fibrosis. She is a worldrenowed expert in her field.

Medical Director, Clinical Research Services

Co-Director, Adult Cystic Fibrosis Program

<u>Director, Cystic Fibrosis Therapeutics Development Center Adult Program</u>

**Professor** 


Division of Pulmonary, Critical Care & Sleep Medicine

**Department of Medicine** 

**Division of Pediatric Pulmonary Medicine** 

**Department of Pediatrics** 


President, Medical Staff



- Bronchiectasis Treatment Program
- Cystic Fibrosis Program (Adult)
- Pulmonary Diagnostic Center (Pediatric)



- Cystic Fibrosis (CF)
- · Pediatric Lung Disease



• Cystic Fibrosis (CF)



- BEACON-CF: Investigational mRNA Therapy for Cystic Fibrosis
- <u>Determining How Parenthood Affects Cystic Fibrosis</u>
  Patients
- Effects of Pregnancy for Cystic Fibrosis Patients
- Investigational Gene Therapy for Adults with CF
- <u>Understanding Reproductive Health Concerns in Men</u> with CF

## **Special Interests**

#### Research Interests

Cystic Fibrosis, clinical research, clinical trial design, sexual and reproductive health

## **Board Certification**

11/2008: ABP, Subspecialty in Pediatric Pulmonary 10/2006: ABIM, Subspecialty in Pulmonary Disease 8/2004: American Board of Internal Medicine

8/2002: American Board of Pediatrics

### Education

### Education

**1998** Duke University Medical Center (Durham, NC)

1993 Stanford University (Stanford, CA)

2015 University of Colorado, Aurora, CO

## Residency

1998 - 2002 Duke University Medical Center

## **Fellowship**

2002 - 2006 Duke University Medical Center

# **Teaching & Professional Positions**

2019-present

Professor (tenured)

Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program

Departments of Internal Medicine and Pediatrics

**Pulmonary Divisions** 

National Jewish Health

Denver, CO

2019-present

Professor

Departments of Internal Medicine and Pediatrics

**Pulmonary Divisions** 

University of Colorado

Aurora, CO

2014-present

Medical Staff

**Pulmonary Medicine** 

Saint Joseph Hospital

Denver, CO

2014-2019

Associate Professor (tenured, 2019)

Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program

Departments of Internal Medicine and Pediatrics

**Pulmonary Divisions** 

National Jewish Health

Denver, CO

2014-2019

**Associate Professor** 

Departments of Internal Medicine and Pediatrics

**Pulmonary Divisions** 

University of Colorado

Aurora, CO

2009-present

Medical Staff

Department of Pulmonology

Children's Hospital Colorado

Aurora, CO

2009-2014

**Assistant Professor** 

Associate Adult CF Program Director (2011-2014)

Departments of Medicine and Pediatrics

**Pulmonary Divisions** 

National Jewish Health

Denver, CO

2009-2014

**Assistant Professor** 

Departments of Medicine and Pediatrics

**Pulmonary Divisions** 

University of Colorado

Aurora, CO

2006-2009

**Assistant Professor** 

Adult Cystic Fibrosis Program Director, Associate CF Center Director

Departments of Internal Medicine and Pediatrics

**Pulmonary Divisions** 

University of New Mexico Albuquerque, NM

### **Academic Affiliations**

2009-Present: Professor, Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine and the Department of Pediatrics, Pulmonary Division, University of Colorado Denver.

# **Professional Memberships**

Member, American Thoracic Society European Cystic Fibrosis Society European Respiratory Society

## Awards & Recognition

2023: Distinguished Achievement Award, American Thoracic Society, New York, NY

2022: CF Trailblazer Award, Emily's Entourage, Merion Station, PA

2022: William J. Martin II Distinguished Achievement Award, American Thoracic Society Public Advisory Roundtable, New York, NY

2020: American Society for Clinical Investigation, Elected Member

2018: ATS Fellow, Inaugural Class, American Thoracic Society, New York, NY

2017: Founder's Award, United States Adult Cystic Fibrosis Association, Indianapolis, IN

2016: Physician of the Year, Colorado Society for Respiratory Care, Denver, CO

2015: Science Transforming Life Award, National Jewish Health, Denver, CO

2014: Viola Vestal Coulter Research Fellow Award

2009: Cystic Fibrosis Research Institute Professional of the Year Award

2009: Selected participant, AAMC Early Career in Medicine Early Career Women Faculty Professional Development Seminar

2008: Clinical Trials Center New Investigator of the Year Award

2006: Duke University Pulmonary Fellowship Scientific Achievement Award

2005: 2nd Place, Fellows' Clinical Research Presentations, Respiratory Disease Young Investigators Forum

2003: Cystic Fibrosis Foundation Clinical Fellowship

### **Publications**

Heijerman HGM, \* McKone EF\*, Downey DG, Braeckel E,Rowe SM, Tullis E. Mall M, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, **Taylor-Cousar JL\***, and McCoy K\* on behalf of the VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508 delmutation: a double-blind, randomised, phase 3 trial.\*equal contributions Lancet. 2019 Oct 30. pii: S0140-6736(19)32597-8. doi: 10.1016/S0140-6736(19)32597-8. PMID: 31679946

Middleton PG\*, Mall MA\*, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, **Taylor-Cousar JL**, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM\*\* and Jain R\*\* for the VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation. *New Eng J Med. 2019. Epub ahead of print* 

Downey DG and **Taylor-Cousar JL.** Challenges and opportunities in the development of future CFTR modulator options for people with CFPMID: 31672556

Keating D, Sass L Burr L, Daines C, Rowe S, Savage J, Simard C, Xuan F, Van Goor F, Robertson S, McKee C, Waltz D, Marigowda G, and **Taylor-Cousar JL** (corresponding author). VX-445 in Combination with Tezacaftor-Ivacaftor in Phe508del Homozygous and Heterozygous Patients with Cystic Fibrosis. *N Engl J Med* 2018; 379:1612-1620 DOI: 10.1056/NEJMoa1807120 PMID: 30334692

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone E, Plant B, Paris D, Ramsey B, **Taylor-Cousar JL**, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and One or Two *F508del-CFTR* Alleles. *N Engl J Med* 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119 *PMID*: 303334693

## **Contact Information**

• Office: 877.225.5654

### Locations

National Jewish Health Main Campus 1400 Jackson Street Denver, CO 80206 Saint Joseph Hospital 1375 E 19th Ave. Denver, CO 80218